KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
AbbVie
Astellas Pharma Inc
Amgen
AbbVie
Actuate Therapeutics Inc.
Eli Lilly and Company
AstraZeneca
QuantumLeap Healthcare Collaborative
Revolution Medicines, Inc.
Hoffmann-La Roche
Norwegian University of Science and Technology
Gustave Roussy, Cancer Campus, Grand Paris
GlaxoSmithKline
Università Vita-Salute San Raffaele
University of Kentucky
Tesaro, Inc.
AbbVie
Weill Medical College of Cornell University
AbbVie
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Tesaro, Inc.
AbbVie
Sanofi
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
DEKA Biosciences
Mario Negri Institute for Pharmacological Research
Shandong Cancer Hospital and Institute